AbbVie Inc

ABBV: XNYS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|y&LOCK|R^LOCK|$M%&rP

AbbVie Earnings: Higher 2025 Guidance Projects Immunology Confidence Despite Potential Tariff Hit

AbbVie reported 8.4% revenue growth and 6.5% adjusted diluted EPS growth in the first quarter. Management raised its 2025 adjusted diluted EPS guidance by 10 cents at the midpoint to a range of $12.09-$12.29, but this does not include the Gubra licensing agreement or potential pharma tariffs.

Sponsor Center